Skip to content
Peptide research

IGF-1 DES

Also known as Des(1-3) IGF-1
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A truncated form of IGF-1 marketed to bodybuilders for tenfold anabolic potency and muscle hyperplasia. The potency edge is real biochemistry, but data is almost entirely animal-based; human evidence is essentially absent, with no safety profile established. The headline risk is severe hypoglycemia (seizures, unconsciousness, death), plus an unresolved concern it could fuel existing tumors. Not FDA-approved; supply is unregulated research-grade product.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Enhanced anabolic potency (~10x over native IGF-1)

    Medium

    Extensive animal and cell studies show up to 10-fold greater potency; no human trials exist.

  • Muscle hyperplasia and satellite cell activation

    Speculative

    Extrapolated from general IGF-1 muscle biology; no analog-specific or human studies confirm this.

  • Reduced IGFBP sequestration for greater bioavailability

    Medium

    Binding studies confirm reduced IGFBP affinity; greater bioavailability in humans is inferred, not measured.

Evidence limits

Evidence Level
Preclinical only

All direct evidence for Des(1-3)IGF-1 comes from in vitro cell culture studies and in vivo animal models (rodents). No controlled human clinical trials have been conducted on Des(1-3)IGF-1 specifically. The broader IGF-1 system is well-studied in humans, but systemic IGF-1 supplementation in elderly subjects failed to augment muscle strength or protein synthesis (Adams, 2001). Des(1-3)IGF-1 clinical applications have not yet been evaluated in humans.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Active cancer

    Absolute

    IGF-1 DES is 10x more potent than regular IGF-1. Directly promotes tumor cell proliferation.

  • Diabetic retinopathy

    High

    Potent IGF-1 activity worsens proliferative retinopathy.

  • Hypoglycemia-prone individuals

    High

    Potent glucose-lowering effect. Risk of dangerous hypoglycemia, especially when fasted.

Risk summary(8)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Severe hypoglycemia — IGF-1 DES has insulin-like glucose-lowering effects that can cause seizures, loss of consciousness, brain damage, and death, particularly when combined with insulin or fasting

    High
  • Cancer risk — The IGF-1/IGF1R signaling pathway promotes cell proliferation and survival; elevated IGF-1 is epidemiologically linked to breast, prostate, colorectal, and lung cancers; a potent IGF-1R agonist could accelerate existing tumor growth

    Moderate
  • Organ enlargement (organomegaly) — Animal studies show dose-dependent increases in kidney, heart, liver, lung, and stomach weights (Gillespie et al., 1990)

    Moderate
  • Suppression of endogenous GH/IGF-1 axis — Exogenous IGF-1 administration may suppress natural growth hormone secretion via negative feedback

    Moderate
  • Product quality concerns — Research-grade peptides lack pharmaceutical manufacturing controls; products may contain wrong sequences, contaminants, degradation products, or no active peptide

    High
  • No established human safety profile — All Des(1-3)IGF-1 data is preclinical; adverse effects in humans are unknown and unpredictable

    High
  • Injection site reactions — Localized pain, swelling, or lipohypertrophy at injection sites

    Low
  • Potential acromegalic effects — Chronic IGF-1R activation may cause abnormal tissue growth patterns similar to acromegaly

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.